Search This Site:

Joint Formulary Newsletter

Bedfordshire and Luton Joint Formulary Newsletter

October 2019, Number 1

Incorporates Key Recommendations from The Bedfordshire and Luton Joint Prescribing Committee (JPC) 18th September 2019


The Bedfordshire and Luton Joint Formulary (a combined medicines formulary for use by BCCG, LCCG, Bedford Hospital and the Luton and Dunstable University Hospital) is now ‘live’. It can be accessed here

Unless otherwise stated decisions made apply to all organisations in the Joint Formulary Group.

RED RED - Hospital Only - to be prescribed by a specialist and supplied from secondary care ONLY throughout treatment
AMBER Amber medicines are considered suitable for GP prescribing following specialist initiation
GREEN These medicines are appropriate for initiation in both primary and secondary care. Prescribing is appropriate within licensed or local recommendations
SCG Shared Care - These medicines require specialist initiation and stabilisation. Ongoing division of responsibility for drug and disease monitoring between specialist and GP by a Shared Care Guideline (SCG). If no SCG in place, status reverts to RED.
BLACK A decision has been made by either or both the local or national NHS not to routinely commission this preparation for its licensed indications. DO NOT PRESCRIBE
The following ADDITIONS to the Joint Formulary were agreed at the JPC Committee Meeting

In addition to the NICE Guidance (with JPC action) and inhalers outlined in the JPC October 2019 newsletter, the following additions to the Formulary were noted or ratified by the JPC:

  • Umeclidinium bromide (Incruse®Ellipta®) for COPD – (LAMA) – 2nd choice option
  • Umeclidinium/vilanterol (Anora®Ellipta®) for COPD – (LAMA/LABA) – 2nd choice option
  • Fluticasone/vilanterol (Relvar®Ellipta® powder for inhalation) FOR COPD – (ICS/LABA) – 1st choice option
  • Fluticasone/vilanterol (Relvar®Ellipta® powder for inhalation) FOR ASTHMA 1ST choice option in teenage patients where compliance is a problem
  • Fluticasone/umeclidinium/vilanterol (Trelegy®92 microgram/55 microgam/22 microgram)- Formulary addition – ICS/LAMA/LABA (Triple therapy) – joint first-line option
Hospital Drug and Therapeutic Committee Updates
  • Letrezole: approved for off label use in polycystic ovary syndrome at L and D hospital DTC in July 2019 – Hospital only
  • Trometamol (THAM): retrospective addition at L and D hospital DTC in July 2019, kept in emergency drug room for metabolic acidosis in paediatrics under the advice of a tertiary centre – Hospital only
  • Cetraxel Plus ® (ciprofloxacin and fluocinolone acetonide): for treatment of otitis externa and otitis media approved by Bedford Hospital DTC – Hospital only
CCG Prescribing Committees

BCCG Prescribing Committee

  • none

LCCG Prescribing Committee

  • none
Wound Care Formulary Group (Ratified by the JPC)

No update from the Wound Care Group

Decisions Made By Joint Formulary Group (Ratified by the JPC)
  • Biktarvy® (Bictegravir-emtricitabine-tenofovir alafenamide (B/F/TAF)) – for treating Human immunodeficiency virus-1 (HIV-1) in adults. Commissioned by NHSE
  • Testosterone – products have been added to the formulary in line with gender dysphoria SCG and status changed to amber
  • Lanreotide – RAG status amended to amber
  • Sun creams – updated prescribing criteria added
  • Degaralix – changed to amber
  • Menopur – multidose formulation added

Safety Needles to be made available by GP prescription only for patients who cannot self-inject and require a carer (not a healthcare professional) to administer the insulin.

Bath and shower preparations for dry and pruritic skin conditions – all products to be removed. “Leave-on” emollients to be used instead in line with national guidance.

Insulin pen needles that cost > £5 per 100 needles (all <£5 per 100 needles to be made available). Insulin pen needles of 8mm and 12 mm.
Olaratumab – Marketing Authorisation withdrawn. To be made non formulary with a note to cover historic prescribing.

Scroll to Top